Navigation Links
Molecular aberration signals cancer
Date:2/19/2014

Several scientists, including one at Simon Fraser University, have made a discovery that strongly links a little understood molecule, which is similar to DNA, to cancer and cancer survival.

EMBO Reports, a life sciences journal published by the European Molecular Biology Organization, has just published online the scientists' findings about small non-coding RNAs.

While RNA is known to be key to our cells' successful creation of proteins, the role of small non-coding RNAs, a newly discovered cousin of the former, has eluded scientific understanding for the most part. Until now, it was only surmised that most of these molecules had nothing to do with protein production.

However, scientists at SFU, the University of British Columbia and the B.C. Cancer Agency have discovered that many non-coding RNAs are perturbed in cancerous human cells, including breast and lung, in a specific way. The disturbance, which manifests itself as shorter than normal molecular messaging, also occurs at a specific spot on genes.

"These two identifiable characteristics give cancer-causing non-coding RNAs a chemical signature that makes it easy for scientists to identify them in the early stages of many different types of cancer," says Steven Jones.

The SFU molecular biology and biochemistry professor is this study's senior author, and the associate director and head of bioinformatics at the B.C. Cancer Agency's Genome Sciences Centre.

"These molecules' existence can also be used to classify cancer patients into subgroups of individuals with different survival outcomes," adds Jones. "While the precise reason why a tumour would change the behaviour of genes in this way is not known, it is likely that it represents a mechanism by which the cancer can subvert and takeover the normally well controlled activity of our genes."

This study uncovered non-coding RNAs' cancerous role by using high-throughput sequencing techniques to analyse reams of genetic information on normal and diseased tissue as part of the Cancer Genome Atlas project.

The Cancer Genome Atlas is an ambitious project to characterize the genetic material of more than 500 tumours from more than 20 different cancers. The project provides a goldmine of data for bioinformaticians such as Jones.


'/>"/>

Contact: Carol Thorbes
cthorbes@sfu.ca
778-782-3035
Simon Fraser University
Source:Eurekalert

Related medicine news :

1. Study uncovers molecular keys to invasive bladder cancer
2. Short circuit in molecular switch intensifies pain
3. Molecular nano-spies to make light work of disease detection
4. Research shows molecular, protein targeting therapies may be best treatment for certain lung cancer
5. Molecular Diagnostics Role in Cancer Testing Analyzed in In-demand TriMark Report Published at MarketPublishers.com
6. New molecular targets identified in some hard-to-treat melanomas provide potential treatment option
7. The Association for Molecular Pathology releases position statement on LDTs
8. Polymer coatings based on molecular structures
9. Supercomputers help ORNL researchers identify key molecular switch that controls cell behavior
10. Mayo Clinic: Drug induces morphologic, molecular and clinical remissions in myelofibrosis
11. Maryville, Tennessee based Molecular Pathology Laboratory Network, Inc. (MPLN) Acquires the First FDA Approved High-Throughput DNA Sequencing Analyzer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: